-
公开(公告)号：US20240392034A1
公开(公告)日：2024-11-28
申请号：US18802877
申请日：2024-08-13
Applicant: MORPHOSYS AG
Inventor： Stefan Härtle
IPC: C07K16/30 , A61P35/00 , C07K14/76 , C07K16/42 , G01N33/49 , G01N33/561 , G01N33/574
Abstract: Applicant discloses an anti-idiotypic antibody to MOR202. which when fused to human albumin. shifted the antibody in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
-
公开(公告)号：US20240343822A1
公开(公告)日：2024-10-17
申请号：US18580460
申请日：2022-07-19
Applicant: MORPHOSYS AG
Inventor： Stefan HÄRTLE , Roland BAUMGARTNER
IPC: C07K16/28 , A61K31/138 , A61K31/167 , A61K31/573 , A61K39/00 , A61P13/12 , A61P37/06
CPC classification number: C07K16/2896 , A61K31/138 , A61K31/167 , A61K31/573 , A61P13/12 , A61P37/06 , A61K2039/505 , A61K2039/545
Abstract: The present disclosure relates to the treatment of anti-PLA2R-positive membranous nephropathy. The anti-CD38 antibody, MOR202, is efficacious when administered to patients at certain dosage regimens.
-
3.发明公开公开(公告)号：US20240228654A9
公开(公告)日：2024-07-11
申请号：US18548477
申请日：2022-03-01
Applicant: MORPHOSYS AG
Inventor： Stefan Steidl , Stefan Härtle , Rainer Boxhammer
IPC: C07K16/28
CPC classification number: C07K16/2896 , A61K2039/545 , C07K2317/24 , C07K2317/52 , C07K2317/565
Abstract: The present invention relates to the use of the anti-CD38 antibody felzartamab in the prophylaxis and/or treatment of antibody-mediated rejection (ABMR) of transplants. In accordance with the present invention, felzartamab is effective in the treatment of antibody-mediated renal allograft rejection.
-
4.发明公开公开(公告)号：US20240009196A1
公开(公告)日：2024-01-11
申请号：US18162955
申请日：2023-02-01
Applicant: MORPHOSYS AG
Inventor： Jan ENDELL , Rainer BOXHAMMER , Mark WINDERLICH
IPC: A61K31/519 , A61K39/395 , C07K16/28 , A61P35/00
CPC classification number: A61K31/519 , A61K39/3955 , C07K16/2803 , A61P35/00 , A61K2039/505
Abstract: The present disclsoure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
-
公开(公告)号：US20230014026A1
公开(公告)日：2023-01-19
申请号：US17354442
申请日：2021-06-22
Applicant: MorphoSys AG , Gilead Sciences, Inc.
Inventor： Jan ENDELL , Günter FINGERLE-ROWSON , Mark Ping CHAO
Abstract: The present disclosure is directed to a combination therapy comprising an antibody or antibody fragment specific for CD19 and a polypeptide that blocks the SIRPα-CD47 innate immune checkpoint for use in the treatment of cancer, in particular hematological cancer such as leukemia or lymphoma.
-
Patent Agency Ranking
公开(公告)号：US20220242952A1
公开(公告)日：2022-08-04
申请号：US17605285
申请日：2020-05-04
Applicant: MORPHOSYS AG
Inventor： Christian KUFFER , Guenter FINGERLE-ROWSON , Mark WINDERLICH , Jan ENDELL
Abstract: The present disclosure provides characteristics and biomarkers in patients that benefit from treatment with anti-CD19 antibodies (MOR00208, XmAb5574). Furthermore, the present application relates to anti-CD19 antibodies for the treatment of leukemia or lymphoma in patients having a peripheral NK cell count at baseline of less or equal to 100 NK cells/μl
-
公开(公告)号：US11352620B2
公开(公告)日：2022-06-07
申请号：US17014084
申请日：2020-09-08
Applicant: MorphoSys AG
Inventor： Katja Siegers , Jan Van Den Brulle
Abstract: The invention relates to novel libraries of linear and cyclic peptides, and methods of generating and screening such libraries for biological, pharmaceutical and other uses.
-
公开(公告)号：US20200377594A1
公开(公告)日：2020-12-03
申请号：US16635303
申请日：2018-08-13
Applicant: MORPHOSYS AG
Inventor： Thomas TILLER , Steffen RUNZ , Julia NEUGEBAUER , Andreas BÜLTMANN
Abstract: The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.
-
公开(公告)号：US10655125B2
公开(公告)日：2020-05-19
申请号：US16080738
申请日：2017-03-03
Applicant: MorphoSys AG
Inventor： Roger Müller , Andreas Bültmann , Josef Prassler , Markus Moosmeier
Abstract: The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.
-
公开(公告)号：US10533057B2
公开(公告)日：2020-01-14
申请号：US15569495
申请日：2016-05-13
Applicant: MORPHOSYS AG
Inventor： Stéphane LeClair , Jan Endell , Stefan Härtle
IPC: A61K39/395 , C07K16/28 , A61P35/00 , A61K9/00 , A61K31/573
Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
-
-
-
-
-
-
-
-
-
Search Results
143
records
(took 0.017 seconds)
